Abstract
Cell-based tumor vaccines have been developed on the basis of the hypothesis that tumor cells can be genetically modified to present antigen to T lymphocytes directly. Contrary to expectations, cross-priming is the predominant pathway for activation of tumor-specific CD8+ T cells, while direct presentation of antigen dominates activation of tumor-specific CD4+ T cells. These results pose interesting paradoxes for the generation of immune responses, and have definite implications for the development of anti-cancer vaccines.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Author information
Authors and Affiliations
Additional information
Received: 10 October 1997 / Accepted 10 January 1998
Rights and permissions
About this article
Cite this article
Armstrong, T., Pulaski, B. & Ostrand-Rosenberg, S. Tumor antigen presentation: changing the rules. Cancer Immunol Immunother 46, 70–74 (1998). https://doi.org/10.1007/s002620050463
Issue Date:
DOI: https://doi.org/10.1007/s002620050463